PainReform to Present at The Noble Capital Markets’ Eighteenth Annual Investor Conference on April 20th
TEL AVIV, Israel, – April 12, 2022 – PainReform Ltd. (Nasdaq: PRFX), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, Chief Executive Officer of PainReform will present at the Noble Capital Markets’ Eighteenth Annual Investor Conference being held on April 20-21, 2022 at the Hard Rock […]
PainReform to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest onMarch 28th – 30th
Tel Aviv, Israel – March 21, 2022 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced it will present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28th – 30th from 9:00 […]
PainReform Provides Year-End Business Update; On track to Commence Phase 3 Trial of PRF-110 for Non-Opiate Post-Operative Pain Relief in the Second Half of 2022
Tel Aviv, Israel – March 17, 2022 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a business update for the year ended December 31, 2021. Ilan Hadar, Chief Executive Officer, stated, “We remain on track to commence our Phase 3 […]
PainReform Provides Business Update for the Third Quarter of 2021
Reports continued progress towards commencing Phase 3 clinical trials Announces Selection of Pharmaceutics International, Inc.as U.S. Manufacturer of PRF-110 for Upcoming Phase 3 Trial Tel Aviv, Israel – November 16, 2021 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a […]
PainReform to Present at Dawson James Securities 6th Annual Small Cap Growth Conference on October 21, 2021
Tel Aviv, Israel – October 14, 2021 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, Chief Executive Officer of PainReform, will present at the Dawson James Securities Small Cap Growth Conference being held on October 21, 2021 […]
PainReform Provides Business Update for the Second Quarter of 2021
Tel Aviv, Israel – August 16, 2021 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a business update for the second quarter ended June 30, 2021. “We are continuing the steady progress towards commencement of our Phase 3 clinical trials […]
PainReform Provides Business Update for the First Quarter of 2021
HERZLIYA, Israel – May 13, 2021 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a business update for the first quarter ended March 31, 2021. The Company also announces it has finalized the protocol for its Phase 3 clinical trials […]
PainReform Provides Year-End Business Update and Reports Progress Towards Commencing Phase 3 Trial of PRF-110 for Non-Opiate Post-Operative Pain Relief
HERZLIYA, Israel – March 17, 2021 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a year-end business update. The Company also reported it has filed its annual report on Form 20-F. Significant events and achievements during the fourth quarter […]
PainReform to Participate at M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference
HERZLIYA, Israel – March 11, 2021 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, CEO of PainReform, has been invited to present at the Inaugural Emerging Growth Virtual Conference, hosted by M Vest LLC and Maxim […]
PainReform Announces $6.0 Million Private Placement
HERZLIYA, Israel – March 8, 2021 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics,today announced that it has entered into securities purchase agreements with certain institutional investors to raise approximately $6.0 million through the private placement of 1,304,346 ordinary shares and […]
